STOCK TITAN

LeMaitre Vascular (LMAT) 10-K Filings

LMAT NASDAQ

Here are the 10-K annual reports from LeMaitre Vascular, Inc. (LMAT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow LMAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LMAT filings page.

Rhea-AI Summary

LeMaitre Vascular describes a growing, acquisition‑driven vascular device and tissue business with expanding global reach and regulatory complexity. The company sells peripheral vascular devices and human tissue cryopreservation services, focused on vascular surgeons and, increasingly, cardiac surgeons.

LeMaitre estimates the peripheral vascular device market exceeds $9 billion, with about $1 billion addressable by its products. In 2025, roughly 95% of net sales came from territories served by its 160‑person direct sales force, and no single product type exceeded 20% of revenue. Biologic products, including XenoSure, CardioCel, VascuCel, Omniflow II, Artegraft and RestoreFlow allografts, represented 53% of 2025 sales.

The company has completed 25 acquisitions since inception and continues to relocate most manufacturing to its Burlington, Massachusetts headquarters, while maintaining specialized facilities in New Jersey and Illinois. Recent initiatives include MDR and UKCA recertifications, CE marking for Artegraft, expansion of allograft cleanroom capacity, and a new Dublin distribution center to support European tissue sales. LeMaitre also discloses an FDA warning letter at its North Brunswick facility and a January 2026 cybersecurity incident it believes has not had a material financial impact, both highlighted as key risk factors.